Cargando…
CD39 and CD73 as Promising Therapeutic Targets: What Could Be the Limitations?
Autores principales: | Battastini, Ana Maria Oliveira, Figueiró, Fabricio, Leal, Daniela Bitencourt Rosa, Doleski, Pedro Henrique, Schetinger, Maria Rosa Chitolina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8014611/ https://www.ncbi.nlm.nih.gov/pubmed/33815115 http://dx.doi.org/10.3389/fphar.2021.633603 |
Ejemplares similares
-
Nucleotide Analog ARL67156 as a Lead Structure for the Development of CD39 and Dual CD39/CD73 Ectonucleotidase Inhibitors
por: Schäkel, Laura, et al.
Publicado: (2020) -
Exploring CD39 and CD73 Expression as Potential Biomarkers in Prostate Cancer
por: Gardani, Carla Fernanda Furtado, et al.
Publicado: (2023) -
CD73: A Promising Biomarker in Cancer Patients
por: Turiello, Roberta, et al.
Publicado: (2020) -
Cytokine-Induced Killer Cells Express CD39, CD38, CD203a, CD73 Ectoenzymes and P1 Adenosinergic Receptors
por: Horenstein, Alberto L., et al.
Publicado: (2018) -
Low expression of CD39 and CD73 genes in centenarians compared with octogenarians
por: Crooke, Almudena, et al.
Publicado: (2017)